Takeda Pharmaceutical (TAK) Expected to Announce Earnings on Wednesday

Key Points

• Q4 2026 results are due before the open on Wednesday, May 13, 2026 at 6:00 AM ET; analysts forecast EPS ($0.0754) and revenue of $7.1689 billion.
• TAK opened at $16.74 with a 12‑month range of $12.99–$18.90, a market cap of $53.28 billion and a P/E of 69.84, with the 50‑day SMA at $17.90 and the 200‑day SMA at $16.29.
• Analyst sentiment is mixed but tilted positive—average rating is a "Moderate Buy" after recent upgrades from firms including Morgan Stanley and Sanford C. Bernstein—and institutional investors hold about 9.17% of the stock.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) is expected to release its Q4 2026 results before the market opens on Wednesday, May 13th. Analysts expect Takeda Pharmaceutical to post earnings of ($0.0754) per share and revenue of $7.1689 billion for the quarter. Parties can check the company's upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 6:00 AM ET.

Takeda Pharmaceutical Stock Up 1.2%

TAK stock opened at $16.74 on Wednesday. Takeda Pharmaceutical has a twelve month low of $12.99 and a twelve month high of $18.90. The company has a quick ratio of 0.65, a current ratio of 1.19 and a debt-to-equity ratio of 0.56. The company has a market cap of $53.28 billion, a PE ratio of 69.84 and a beta of -0.06. The business's 50-day simple moving average is $17.90 and its 200 day simple moving average is $16.29.

Institutional Investors Weigh In On Takeda Pharmaceutical

A number of hedge funds have recently made changes to their positions in the company. Franklin Resources Inc. boosted its position in Takeda Pharmaceutical by 3.8% in the third quarter. Franklin Resources Inc. now owns 19,458 shares of the company's stock valued at $285,000 after buying an additional 713 shares in the last quarter. Lido Advisors LLC increased its holdings in shares of Takeda Pharmaceutical by 4.4% during the third quarter. Lido Advisors LLC now owns 27,714 shares of the company's stock worth $406,000 after buying an additional 1,166 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company's stock valued at $55,000 after acquiring an additional 1,292 shares during the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Takeda Pharmaceutical by 192.2% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company's stock valued at $40,000 after acquiring an additional 1,684 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC boosted its holdings in shares of Takeda Pharmaceutical by 14.0% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 17,584 shares of the company's stock worth $274,000 after acquiring an additional 2,153 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Zacks Research raised Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 3rd. Weiss Ratings restated a "hold (c)" rating on shares of Takeda Pharmaceutical in a research note on Wednesday, April 29th. Morgan Stanley began coverage on shares of Takeda Pharmaceutical in a research note on Tuesday, January 13th. They set an "overweight" rating on the stock. Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a "market perform" rating to an "outperform" rating in a report on Wednesday, April 8th. Finally, Wall Street Zen upgraded shares of Takeda Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Saturday, April 11th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy".

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited NYSE: TAK is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.